Monobactamics (Aztreonam)

Exclusive Gram-Negative Spectrum Wall Inhibitors

Aztreonam represents the only monobactam formulation available in clinical practice. Its monocyclic ring structure gives it unique immunological and spectral properties that differentiate it from the rest of the beta-lactams.

Mechanism

💊 Commercial Names

Azactam, Aztreonam Kern, Salvat-Aztreonam.

🔬 Pharmacological Group

Monocyclic beta-lactams (Monobactamics). Strict aerobic Gram-negative spectrum.

Mechanism of Action

Its molecular design selectively focuses on specific PBPs of Gram-negative bacteria:

Inhibition of PBP3 in Gram-Negative Aerobes: Aztreonam has an almost exclusive binding affinity for the PBP3 of aerobic Gram-negative bacteria with a nosocomial clinical course. By selectively blocking this dural enzyme, it inhibits the formation of bacterial division septa, inducing abnormal filamentous growth of the bacteria and its subsequent spontaneous osmotic cell lysis.
Unique stability against Metallo-beta-lactamases (MBL): Due to the molecular configuration of its monocyclic central ring, aztreonam is resistant to hydrolysis mediated by metallo-beta-lactamases (Ambler Class B, such as NDM and VIM), becoming the only beta-lactam active against pathogens that produce these enzymes (but is destroyed by ESBL or KPC co-expressed regularly).
No Affinity for Gram-Positive and Anaerobic PBPs: It lacks affinity for the specific PBPs of Gram-positive cocci or anaerobic microorganisms, which supports its null activity against these groups.

Pharmacokinetics

Key Pharmacokinetics

Parameter	Quantitative Pharmacokinetic Profile
Routes of Administration	Intravenous (IV), Intramuscular (IM), Inhaled (specific for cystic fibrosis).
Distribution and CSF	Excellent extracellular distribution in soft tissues, lung and bile fluid. It effectively penetrates the inflamed dural CSF in high doses (reaching 15-20% of plasma levels).
Protein Binding	Moderate (~56-60%). Not relevant bilirubin displacer.
Metabolism	It undergoes minimal hepatic metabolism due to inactive conjugation (<10%).
Excretion and Half-Life	It is eliminated unchanged in the urine by 60-70% through glomerular filtration and tubular secretion. Elimination half-life (t_1/2): 1.5 to 2.0 hours in healthy young adults; It can last up to 6.0-8.0 hours in end-stage renal failure.

Antimicrobial Spectrum

Gram-Negative Aerobes: Excellent activity against common enterobacteria, Haemophilus influenzae, Neisseria meningitidis and with active coverage of Pseudomonas aeruginosa.
Spectrum Gaps: No activity against Gram-positives (including Streptococcus spp. and Staphylococcus spp.), anaerobes of all types and atypical microorganisms.

Indicators and dose

Dosage and Adjustment

Adults (Serious infections): 1 to 2 g IV every 6 to 8 hours (maximum dose 8 g/day).
Adjustment in Kidney Failure:
- Cl_cr 10-30 mL/min: Start with a loading dose of 1 or 2 g, and continue with 50% of the standard dose every 8 hours.
- Cl_cr < 10 mL/min: Continue with 25% of the standard dose every 8-12 hours.

Security

Contraindications and ADRs

Contraindications: Proven specific allergy to aztreonam.
Adverse Effects (ADR): Excellent biological safety profile. Transient elevation of serum transaminases in less than 2% of cases. Mild skin reactions and pain at the local injection site.

Immunological Safety in Patients Allergic to Penicillin

Unlike other penicillins, cephalosporins or carbapenems, Aztreonam has a dural monocyclic molecular structure of very low immunogenicity that does not present allergogenic cross-reactivity with most beta-lactams. The only common antigenic determinant it shares is with Ceftacidime (both have an identical aminothiazole side chain). Therefore, Aztreonam is the only safe beta-lactam that can be safely used in patients with proven immediate allergy (anaphylaxis) to penicillin.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousCarbapenems NextGlycopeptides and Lipoglycopeptides

System: Antimicrobial and Infectious
Cluster: Exclusive Gram-Negative Spectrum Wall Inhibitors

Download Epistemis